Project Grant R01HL188263
Award Date 8/13/26
Completion Date 6/30/31
Dollars Obligated $847K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded New York University School of Medicine $186,706 for a K23 Career Development Award on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will evaluate multi-level contexts and barriers affecting primary care clinicians' prescribing of remote patient monitoring (RPM) for hypertension management, then design and test an electronic health record-based prescribing workflow (EHR-RPM) to increase RPM...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests...
- The National Heart Lung and Blood Institute awarded New York University $510,538 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a hybrid effectiveness-implementation study integrating the HEARTS package—a World Health Organization–recommended strategy comprising healthy lifestyle counseling, evidence-based treatment protocols, access to medicines, risk-based care, task-sharing, and systems monitoring—into primary healthcare centers in Nigeria...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Institutes of Health Office of the Director awarded New York University School of Medicine $100,001 under the Vision Research program (CFDA 93.867) on August 1, 2026, to develop and evaluate BARBER-CLIP, a community-engaged, barbershop-based tele-screening model for diabetic retinopathy. The recipient will train community health workers to screen men for diabetic retinopathy in barbershops and refer positive cases to ophthalmologic care, building on a successful...
- The National Heart, Lung, and Blood Institute awarded Oregon Health & Science University $2,141,996 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and implement Community Vital Signs (CVS) strategies for identifying undiagnosed hypertension in Nigeria. The project adapts community-based screening interventions to increase blood pressure screening among adults over 18 years of age and connect patients to primary care for hypertension...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Louisiana State University Health Sciences Center New Orleans $1,008,719 on April 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to screen and validate microRNA targets for neurogenic hypertension. The work addresses treatment-resistant neurogenic hypertension, which accounts for a substantial share of resistant hypertension cases and stems from increased sympathetic outflow from the...
- The National Heart, Lung, and Blood Institute awarded New York University $1,692,126 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect the molecular mechanisms and therapeutic potential of CHROMR, a long noncoding RNA upregulated in atherosclerotic cardiovascular disease. The research will map CHROMR-protein interfaces and design steric-blocking oligonucleotides to selectively disrupt the CHROMR-IRF2BP2 interaction, decoupling its pro-inflammatory...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded $305,471 to ISA Associates, Inc. on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and pilot test a mobile stress management and medication adherence intervention targeting hypertension among men employed in manual and trade labor. The project addresses occupational stress as a driver of hypertension risk in construction, repair, production, and transportation workers, who experience...